Tags

Type your tag names separated by a space and hit enter

Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

Abstract

Etiologic differences between subtypes of breast cancer defined by estrogen receptor (ER) and progesterone receptor (PR) status are not well understood. The authors evaluated associations of hormone-related factors with breast cancer subtypes in a population-based case-control study involving 1,409 ER-positive (ER+)/PR-positive (PR+) cases, 712 ER-negative (ER-)/PR-negative (PR-) cases, 301 ER+/PR- cases, 254 ER-/PR+ cases, and 3,474 controls aged 20-70 years in Shanghai, China (phase I, 1996-1998; phase II, 2002-2005). Polytomous logistic regression and Wald tests for heterogeneity across subtypes were conducted. Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone receptor status. Among postmenopausal women, higher parity (≥2 children vs. 1) was associated with reduced risk (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.52, 0.91) and higher body mass index (BMI; weight (kg)/height (m)(2)) with increased risk (highest quartile: OR = 2.40, 95% CI: 1.65, 3.47) of the ER+/PR+ subtype but was unrelated to the ER-/PR- subtype (for parity, P(heterogeneity) = 0.02; for BMI, P(heterogeneity) < 0.01). Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.62) and alcohol consumption (OR = 1.59, 95% CI: 1.01, 2.51) appeared to be preferentially associated with the ER+/PR- subtype. These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may play different roles in subtypes of breast cancer. More research is needed to better understand the etiology of 2 relatively rare subtypes, ER+/PR- tumors and ER-/PR+ tumors.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203-1738, USA.

    , , , , , , , , ,

    Source

    American journal of epidemiology 174:6 2011 Sep 15 pg 661-71

    MeSH

    Adult
    Age Factors
    Aged
    Biomarkers, Tumor
    Body Mass Index
    Breast Neoplasms
    China
    Female
    Follow-Up Studies
    Humans
    Middle Aged
    Receptors, Estrogen
    Receptors, Progesterone
    Retrospective Studies
    Risk Assessment
    Risk Factors
    Urban Population
    Young Adult

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    21768404

    Citation

    Bao, Ping-Ping, et al. "Association of Hormone-related Characteristics and Breast Cancer Risk By Estrogen Receptor/progesterone Receptor Status in the Shanghai Breast Cancer Study." American Journal of Epidemiology, vol. 174, no. 6, 2011, pp. 661-71.
    Bao PP, Shu XO, Gao YT, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol. 2011;174(6):661-71.
    Bao, P. P., Shu, X. O., Gao, Y. T., Zheng, Y., Cai, H., Deming, S. L., ... Zheng, W. (2011). Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. American Journal of Epidemiology, 174(6), pp. 661-71. doi:10.1093/aje/kwr145.
    Bao PP, et al. Association of Hormone-related Characteristics and Breast Cancer Risk By Estrogen Receptor/progesterone Receptor Status in the Shanghai Breast Cancer Study. Am J Epidemiol. 2011 Sep 15;174(6):661-71. PubMed PMID: 21768404.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. AU - Bao,Ping-Ping, AU - Shu,Xiao Ou, AU - Gao,Yu-Tang, AU - Zheng,Ying, AU - Cai,Hui, AU - Deming,Sandra L, AU - Ruan,Zhi-Xian, AU - Su,Yinghao, AU - Gu,Kai, AU - Lu,Wei, AU - Zheng,Wei, Y1 - 2011/07/18/ PY - 2011/7/20/entrez PY - 2011/7/20/pubmed PY - 2011/11/9/medline SP - 661 EP - 71 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 174 IS - 6 N2 - Etiologic differences between subtypes of breast cancer defined by estrogen receptor (ER) and progesterone receptor (PR) status are not well understood. The authors evaluated associations of hormone-related factors with breast cancer subtypes in a population-based case-control study involving 1,409 ER-positive (ER+)/PR-positive (PR+) cases, 712 ER-negative (ER-)/PR-negative (PR-) cases, 301 ER+/PR- cases, 254 ER-/PR+ cases, and 3,474 controls aged 20-70 years in Shanghai, China (phase I, 1996-1998; phase II, 2002-2005). Polytomous logistic regression and Wald tests for heterogeneity across subtypes were conducted. Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone receptor status. Among postmenopausal women, higher parity (≥2 children vs. 1) was associated with reduced risk (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.52, 0.91) and higher body mass index (BMI; weight (kg)/height (m)(2)) with increased risk (highest quartile: OR = 2.40, 95% CI: 1.65, 3.47) of the ER+/PR+ subtype but was unrelated to the ER-/PR- subtype (for parity, P(heterogeneity) = 0.02; for BMI, P(heterogeneity) < 0.01). Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.62) and alcohol consumption (OR = 1.59, 95% CI: 1.01, 2.51) appeared to be preferentially associated with the ER+/PR- subtype. These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may play different roles in subtypes of breast cancer. More research is needed to better understand the etiology of 2 relatively rare subtypes, ER+/PR- tumors and ER-/PR+ tumors. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/21768404/Association_of_hormone_related_characteristics_and_breast_cancer_risk_by_estrogen_receptor/progesterone_receptor_status_in_the_shanghai_breast_cancer_study_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwr145 DB - PRIME DP - Unbound Medicine ER -